

DLL3

Catalog # PVGS1827

Specification

DLL3 - Product Information

Primary Accession **Species**Cynomolgus

A0A2K5WSR1

Sequence

Ala27-Arg488

Purity

> 95% as determined by Bis-Tris PAGE

Endotoxin Level

Less than 1EU per µg by the LAL method.

Biological Activity

Immobilized DLL3, His, Cynomolgus (Cat.No.: Z03947) at 1 μ g/ml (100 μ l/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag

Expression System

HEK293

Theoretical Molecular Weight

49.21 kDa

Formulation

Lyophilized from 0.22 µm filtered solution in 20 mM Tris, 200 mM NaCl, 200 mM L-arginine (pH 8.5).

Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂0 more than 100 μ g/ml.


Storage & Stability

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

DLL3 - Additional Information

Target Background

Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.



Tel: 858.875.1900 Fax: 858.875.1999



DLL3 - Protein Information

DLL3 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

DLL3 - Images